MedTrace Logo

Measuring Heart and Lung Function in Critical Care

NCT03424798 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-02-07

No results posted yet for this study

Summary

This is a feasibility study of the use of a novel technique called 'Inspiwave' to measure heart and lung function in adult patients in critical care.

The preliminary work has already been undertaken in animal models and in healthy volunteers. The ultimate aim of this study is to develop a clinical tool for measuring (and therefore being able to make treatment changes based on) indices of heart and lung function in critical care patients. This study is the first assessment of the technique in this population, and whilst we know it works in patients undergoing general anaesthesia, we now need to assess whether Inspiwave can be used at all in critical care patients who may have much more physiological derangement. The purpose of this phase of the research is to determine whether it is feasible to use Inspiwave in critical care.

Inspiwave generates a sinusoidally modulated tracer gas signal in the inspired air. It also measures the resulting signal in the expired air. The unique handling of this signal by the patient can used be to derive key variables related to cardiopulmonary function such as lung volume, pulmonary blood flow, the deadspace (wasted ventilation) and the degree to which ventilation and blood flow are non-uniform. These are 'vital signs' in sick patients, yet are currently technically difficult to measure, particularly non-invasively.

Conditions

  • Respiratory Distress Syndrome, Adult
  • Critical Illness
  • Mechanical Ventilation Complication
  • Haemodynamic Instability
  • Gas Exchange Impairment

Interventions

DEVICE

Inspiwave

patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-21
Primary Completion
2019-09-30
Completion
2020-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03424798 on ClinicalTrials.gov